Watchdog set to reject four drugs for kidney cancer on the NHS.
O'Dowd
Adrian
A
D000911:Antibodies, Monoclonal / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000191:economics; D000068258:Bevacizumab; D017277:Drug Approval / Q000191:economics; D016527:Drug Costs; D006801:Humans; D007211:Indoles / Q000191:economics; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000191:economics; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000191:economics; D011758:Pyrroles / Q000191:economics; D020123:Sirolimus / Q000031:analogs & derivatives / Q000191:economics; D000077157:Sorafenib; D013222:State Medicine / Q000191:economics; D000077210:Sunitinib; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; D000077157:Sorafenib; D000077210:Sunitinib; D020123:Sirolimus